Compare PRCT & PTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRCT | PTA |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2021 | N/A |
| Metric | PRCT | PTA |
|---|---|---|
| Price | $21.41 | $19.08 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $35.44 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 136.7K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.31% |
| EPS Growth | ★ 1.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $308,054,000.00 | N/A |
| Revenue This Year | $31.34 | N/A |
| Revenue Next Year | $24.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.22 | N/A |
| 52 Week Low | $19.35 | $18.13 |
| 52 Week High | $62.17 | $20.92 |
| Indicator | PRCT | PTA |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 45.56 |
| Support Level | $19.35 | $19.04 |
| Resistance Level | $29.27 | $19.78 |
| Average True Range (ATR) | 1.72 | 0.26 |
| MACD | -0.85 | -0.03 |
| Stochastic Oscillator | 8.21 | 29.73 |
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.